ASX - By Stock
|
OSL |
Re:
Ann: Two more PANCOSIL Trial treatments using OncoSil device
|
|
Abloke
|
63 |
13K |
0 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
63
|
13K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Placement and Entitlement Offer to raise up to $7.1 million
|
|
Abloke
|
118 |
30K |
1 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
118
|
30K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Placement and Entitlement Offer to raise up to $7.1 million
|
|
Abloke
|
118 |
30K |
0 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
118
|
30K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Placement and Entitlement Offer to raise up to $7.1 million
|
|
Abloke
|
118 |
30K |
0 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
118
|
30K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Placement and Entitlement Offer to raise up to $7.1 million
|
|
Abloke
|
118 |
30K |
1 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
118
|
30K
|
1
|
|
ASX - By Stock
|
OSL Biotech |
Re:
Time to go long big on $OSL?
|
|
Abloke
|
17 |
7.0K |
1 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
17
|
7.0K
|
1
|
|
ASX - By Stock
|
OSL Biotech |
Re:
Time to go long big on $OSL?
|
|
Abloke
|
17 |
7.0K |
1 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
17
|
7.0K
|
1
|
|
ASX - By Stock
|
OSL Biotech |
Re:
OSL in recovery?
|
|
Abloke
|
8 |
3.0K |
1 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
8
|
3.0K
|
1
|
|
ASX - By Stock
|
OSL Biotech |
Re:
OSL in recovery?
|
|
Abloke
|
8 |
3.0K |
1 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
8
|
3.0K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
OncoSil Insurance Adoption
|
|
Abloke
|
67 |
23K |
2 |
25/01/24 |
25/01/24 |
ASX - By Stock
|
67
|
23K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
OncoSil advancements in Pancreatic Cancer Treatment
|
|
Abloke
|
13 |
2.8K |
1 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
13
|
2.8K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
OncoSil advancements in Pancreatic Cancer Treatment
|
|
Abloke
|
13 |
2.8K |
1 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
13
|
2.8K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil onboards first patient in PANCOSIL Clinical Trial
|
|
Abloke
|
19 |
5.3K |
3 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
19
|
5.3K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil gaining traction in the Israeli healthcare market
|
|
Abloke
|
6 |
2.4K |
0 |
25/11/23 |
25/11/23 |
ASX - By Stock
|
6
|
2.4K
|
0
|
|
ASX - By Stock
|
RDM |
Re:
Red Metal Banter
|
|
Abloke
|
486 |
128K |
2 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
486
|
128K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Abloke
|
65 |
17K |
1 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
65
|
17K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Mr Brian Leedman to retire from the Board of OncoSil
|
|
Abloke
|
14 |
5.0K |
0 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
14
|
5.0K
|
0
|
|
ASX - By Stock
|
BRL |
Re:
Canadian opportunities
|
|
Abloke
|
5 |
4.7K |
6 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
5
|
4.7K
|
6
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
Abloke
|
31 |
12K |
0 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
31
|
12K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Change of Directors Interest Notice - Appendix 3Y OB
|
|
Abloke
|
21 |
6.4K |
1 |
07/07/23 |
07/07/23 |
ASX - By Stock
|
21
|
6.4K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Change of Directors Interest Notice - Appendix 3Y OB
|
|
Abloke
|
21 |
6.4K |
0 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
21
|
6.4K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Entitlement Offer Results and Shortfall Notification
|
|
Abloke
|
133 |
40K |
0 |
11/05/23 |
11/05/23 |
ASX - By Stock
|
133
|
40K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Rights Issue
|
|
Abloke
|
25 |
10K |
0 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
25
|
10K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Rights Issue
|
|
Abloke
|
25 |
10K |
0 |
12/04/23 |
12/04/23 |
ASX - By Stock
|
25
|
10K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Non-renounceable Rights Issue Offer Prospectus
|
|
Abloke
|
122 |
43K |
1 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
122
|
43K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: FY 2023 Strategic Update
|
|
Abloke
|
13 |
6.8K |
0 |
24/02/23 |
24/02/23 |
ASX - By Stock
|
13
|
6.8K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: FY 2023 Strategic Update
|
|
Abloke
|
13 |
6.8K |
1 |
24/02/23 |
24/02/23 |
ASX - By Stock
|
13
|
6.8K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Two key treatment centres treat first patients with OncoSil
|
|
Abloke
|
23 |
9.9K |
0 |
09/02/23 |
09/02/23 |
ASX - By Stock
|
23
|
9.9K
|
0
|
|
ASX - By Stock
|
BRL |
Re:
YEAR'S END
|
|
Abloke
|
2 |
1.5K |
1 |
14/12/22 |
14/12/22 |
ASX - By Stock
|
2
|
1.5K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Change of Director's Interest Notice
|
|
Abloke
|
16 |
6.8K |
1 |
24/11/22 |
24/11/22 |
ASX - By Stock
|
16
|
6.8K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Change of Director's Interest Notice
|
|
Abloke
|
16 |
6.8K |
1 |
24/11/22 |
24/11/22 |
ASX - By Stock
|
16
|
6.8K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Change of Director's Interest Notice
|
|
Abloke
|
16 |
6.8K |
1 |
24/11/22 |
24/11/22 |
ASX - By Stock
|
16
|
6.8K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Change of Director's Interest Notice
|
|
Abloke
|
58 |
15K |
1 |
07/11/22 |
07/11/22 |
ASX - By Stock
|
58
|
15K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Resignation of Director - Dr Martin Cross
|
|
Abloke
|
1 |
891 |
3 |
24/10/22 |
24/10/22 |
ASX - By Stock
|
1
|
891
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil to Present at South-West Connect ASX Showcase
|
|
Abloke
|
11 |
4.3K |
2 |
19/10/22 |
19/10/22 |
ASX - By Stock
|
11
|
4.3K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
AGM VOTE - FREE OPTION & ADDITIONAL COST
|
|
Abloke
|
31 |
12K |
3 |
24/09/22 |
24/09/22 |
ASX - By Stock
|
31
|
12K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
AGM VOTE - FREE OPTION & ADDITIONAL COST
|
|
Abloke
|
31 |
12K |
1 |
24/09/22 |
24/09/22 |
ASX - By Stock
|
31
|
12K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Investor Roadshows
|
|
Abloke
|
17 |
7.5K |
1 |
24/09/22 |
24/09/22 |
ASX - By Stock
|
17
|
7.5K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
ONCOSIL MEDICAL LTD vs SIRTEX MEDICAL?
|
|
Abloke
|
16 |
9.6K |
1 |
13/04/22 |
13/04/22 |
ASX - By Stock
|
16
|
9.6K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Half Yearly Report Results
|
|
Abloke
|
10 |
7.1K |
0 |
08/03/22 |
08/03/22 |
ASX - By Stock
|
10
|
7.1K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Abloke
|
16 |
11K |
0 |
28/01/22 |
28/01/22 |
ASX - By Stock
|
16
|
11K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
Abloke
|
380 |
174K |
2 |
21/01/22 |
21/01/22 |
ASX - By Stock
|
380
|
174K
|
2
|
|
ASX - By Stock
|
RDM |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
Abloke
|
13 |
6.7K |
0 |
12/01/22 |
12/01/22 |
ASX - By Stock
|
13
|
6.7K
|
0
|
|
ASX - By Stock
|
BRL |
Bathurst Resources Upgraded to Buy from Hold by Bell Potter
|
|
Abloke
|
2 |
1.0K |
0 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
2
|
1.0K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: 2021 AGM CEO Presentation
|
|
Abloke
|
10 |
7.2K |
1 |
21/10/21 |
21/10/21 |
ASX - By Stock
|
10
|
7.2K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Issue of Performance Rights
|
|
Abloke
|
2 |
1.4K |
1 |
21/10/21 |
21/10/21 |
ASX - By Stock
|
2
|
1.4K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Prof. Ricky Sharma appointed to the Board of OncoSil
|
|
Abloke
|
11 |
5.5K |
3 |
12/10/21 |
12/10/21 |
ASX - By Stock
|
11
|
5.5K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
Abloke
|
9 |
5.6K |
1 |
23/09/21 |
23/09/21 |
ASX - By Stock
|
9
|
5.6K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
Abloke
|
9 |
5.6K |
0 |
19/09/21 |
19/09/21 |
ASX - By Stock
|
9
|
5.6K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Bell Potter what gives?
|
|
Abloke
|
27 |
17K |
1 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
27
|
17K
|
1
|
|